[go: up one dir, main page]

NL301037I2 - Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan - Google Patents

Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan Download PDF

Info

Publication number
NL301037I2
NL301037I2 NL301037C NL301037C NL301037I2 NL 301037 I2 NL301037 I2 NL 301037I2 NL 301037 C NL301037 C NL 301037C NL 301037 C NL301037 C NL 301037C NL 301037 I2 NL301037 I2 NL 301037I2
Authority
NL
Netherlands
Prior art keywords
solamphetol
pharmaceutically acceptable
salt
acceptable salt
hydrochloride salt
Prior art date
Application number
NL301037C
Other languages
English (en)
Other versions
NL301037I1 (nl
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301037(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of NL301037I1 publication Critical patent/NL301037I1/nl
Publication of NL301037I2 publication Critical patent/NL301037I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL301037C 2005-06-08 2020-03-30 Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan NL301037I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
NL301037I1 NL301037I1 (nl) 2020-04-01
NL301037I2 true NL301037I2 (nl) 2020-05-12

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301037C NL301037I2 (nl) 2005-06-08 2020-03-30 Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan

Country Status (16)

Country Link
US (7) US8440715B2 (nl)
EP (1) EP1890684B1 (nl)
JP (1) JP5024635B2 (nl)
KR (1) KR101335941B1 (nl)
CN (1) CN101217949B (nl)
AU (1) AU2006254899B2 (nl)
BR (1) BRPI0613697A2 (nl)
CA (1) CA2611713C (nl)
DK (1) DK1890684T3 (nl)
ES (1) ES2435403T3 (nl)
FR (1) FR20C1014I2 (nl)
NL (1) NL301037I2 (nl)
PL (1) PL1890684T3 (nl)
RU (1) RU2417077C2 (nl)
TW (2) TWI419681B (nl)
WO (1) WO2006133393A1 (nl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5024635B2 (ja) 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
DE602006012670D1 (de) * 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
KR20120098578A (ko) * 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055944A2 (en) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
JP6530741B2 (ja) 2013-03-13 2019-06-12 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療
PL3021838T3 (pl) 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Leczenie otyłości
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
FI3509582T3 (fi) * 2016-09-06 2024-02-08 Axsome Malta Ltd (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto
US10710958B2 (en) 2016-10-06 2020-07-14 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol compounds and uses thereof
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
AU2018312328B2 (en) 2017-07-31 2022-12-15 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2024102718A1 (en) * 2022-11-07 2024-05-16 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
IL109872A (en) 1993-06-10 2000-12-06 Lilly Co Eli Tetrahydrobenz ¬CD¾ indole-6-carboxamides for use in preventing emesis and pharmaceutical compositions comprising same
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) * 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
DE60221670T2 (de) 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ES2262826T3 (es) 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad.
DE60210976T2 (de) 2001-02-27 2007-05-24 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
JP5024635B2 (ja) * 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
WO2007018496A1 (en) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Methods for treating substance-related disorders
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
JP6530741B2 (ja) * 2013-03-13 2019-06-12 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療

Also Published As

Publication number Publication date
TW201328689A (zh) 2013-07-16
EP1890684A1 (en) 2008-02-27
US20140350098A1 (en) 2014-11-27
US20240239740A1 (en) 2024-07-18
US12209059B2 (en) 2025-01-28
US8877806B2 (en) 2014-11-04
US11753368B2 (en) 2023-09-12
CA2611713C (en) 2013-10-01
US20090312416A1 (en) 2009-12-17
AU2006254899A1 (en) 2006-12-14
PL1890684T3 (pl) 2014-05-30
US20130137764A1 (en) 2013-05-30
ES2435403T3 (es) 2013-12-19
TW200716084A (en) 2007-05-01
US20210078943A1 (en) 2021-03-18
US9604917B2 (en) 2017-03-28
RU2008100019A (ru) 2009-07-20
JP5024635B2 (ja) 2012-09-12
KR101335941B1 (ko) 2013-12-04
EP1890684B1 (en) 2013-08-14
FR20C1014I2 (fr) 2021-04-23
DK1890684T3 (da) 2013-10-14
BRPI0613697A2 (pt) 2011-01-25
WO2006133393A1 (en) 2006-12-14
AU2006254899B2 (en) 2011-11-24
CN101217949B (zh) 2012-10-17
US8440715B2 (en) 2013-05-14
FR20C1014I1 (nl) 2020-06-12
US20190367448A1 (en) 2019-12-05
US10351517B2 (en) 2019-07-16
KR20080035565A (ko) 2008-04-23
NL301037I1 (nl) 2020-04-01
JP2008545795A (ja) 2008-12-18
TWI419681B (zh) 2013-12-21
US20170158622A1 (en) 2017-06-08
RU2417077C2 (ru) 2011-04-27
CN101217949A (zh) 2008-07-09
CA2611713A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NO2024010I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NL301049I1 (nl) Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL301104I2 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat.
NL301065I2 (nl) Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301003I2 (nl) Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl) Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL300865I1 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL301020I2 (nl) Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
NL300990I2 (nl) Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NL301177I1 (nl) tecovirimat of een farmaceutisch aanvaardbaar zout daarvan
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL300996I1 (nl) Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout
NL301304I2 (nl) aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
NO2016016I2 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout